South America Gastroparesis Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Type (Idiopathic, Diabetic, Post-Surgical, and Others), Drug Class (Prokinetic Agents, Botulinum Toxin Injections, and Antiemetic Agents), and Distribution Channel (Retail Pharmacies, Hospital Pharmacies, and Others)

TIPRE00024818 | Pages: 101 | Pharmaceuticals | Sep 2021 | Type: Regional | Status: Published

Market Introduction

SAM region consists of Brazil, Argentina, and Rest of SAM. Brazil is expected to have the major market share in this region. Also, it is projected to grow with highest growth rate. Increasing prevalence of gastroparesis in Brazil is the major cause of the country to witness rapid growth for the market. In addition, the emerging biotech and medical device sector poses opportunities for the gastroparesis market to grow. Some of the prominent countries contributing to the growth of gastroparesis market include Chile, Colombia, Peru, and Bolivia. A significant population suffers from diabetes in these countries. Moreover, presence of well-established manufacturing companies in the regions will further drive the market growth. In addition, implementation of strategic partnerships and collaborations by global market players in the region are estimated to promote the awareness of gastroparesis in the market, which will eventually drive the market growth during the forecast period.

SAM is facing significantly challenging situations due to COVID 19 pandemic. However, the recent pandemic is causing turbulence to the economies of the SAM. A sudden drop in demand for gastroparesis, diabetes, and treatments and production due to labor shortage are some of the major impacts observed in the region. In Central America countries, there is a surge in demand for normal consumer health drugs such as anti-emetic. Some countries across SAM are limiting the sales/purchase of non-prescription drugs in response to COVID-19 to maintain supply and counteract stockpiling/panic buying. The approach differs widely across the region: countries such as Brazil and Argentina have introduced strict limits, while others, such as the Peru and other SAM countries, have not ordered official restrictions.  


Get more information on this report :



Market Overview and Dynamics

The gastroparesis market in SAM is expected to grow from US$ 320.85 million in 2020 to US$ 407.30 million by 2027; it is estimated to grow at a CAGR of 3.5% from 2020 to 2027. Advanced computational technologies such as artificial intelligence (AI) and biomedical engineering hold potential to offer promising solutions for the treatment of gastroparesis. The efficacy of gastric electrical stimulation in improving gastric emptying and reducing symptoms severity in patients with diabetes gastroparesis has already been proven. Moreover, several devices have been awarded with the FDA approval for the treatment of this condition. In February 2015, Medtronic received FDA approval for its Enterra gastric neurostimulator device, which is already available in the market for the treatment of gastroparesis. The device won a regulatory approval for its use in the prevention of nausea and vomiting associated with the idiopathic and diabetic gastroparesis. The growing emphasis on the research pertaining to the gastric electrical stimulation therapy is anticipated to encourage new technology developments in the gastroparesis market, eventually allowing the market players to come up with better alternatives for the existing gastroparesis treatment modalities in the coming years.     

Key Market Segments

The SAM gastroparesis market is segmented on the basis of type, drug class, distribution channel, and country. The SAM gastroparesis market, by type, is segmented into idiopathic, diabetic, post-surgical, and others. The idiopathic segment held the largest share of the market in 2019. The SAM gastroparesis market, by drug class type, is segmented into prokinetic agents, botulinum toxin injection, and antiemetic agents. The prokinetic agents segment held the largest share of the market in 2019. Based on distribution channel, the SAM gastroparesis market is segmented into retail pharmacies, hospital pharmacies, and others. The hospital pharmacies segment held the largest share of the market in 2019. Based on country, the SAM gastroparesis market is segmented into Brazil, Argentina, and rest of SAM. Brazil held the largest market share in 2019.              

Major Sources and Companies Listed

A few major primary and secondary sources referred to for preparing this report on the gastroparesis market in SAM are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are Allergan Plc; Bausch Health Companies Inc. (Salix Pharmaceuticals, Ltd.); Ipca Laboratories Ltd.; Johnson and Johnson Services, Inc.; Pfizer Inc.; and TEVA PHARMACEUTICAL INDUSTRIES LTD.         

Reasons to buy report

  • To understand the SAM gastroparesis market landscape and identify market segments that are most likely to guarantee a strong return.
  • Stay ahead of the race by comprehending the ever-changing competitive landscape for SAM gastroparesis market.
  • Efficiently plan M&A and partnership deals in SAM gastroparesis market by identifying market segments with the most promising probable sales.
  • Helps to take knowledgeable business decisions from perceptive and comprehensive analysis of market performance of various segment form SAM gastroparesis market.
  • Obtain market revenue forecast for market by various segments from 2021-2028 in SAM region.

SAM Gastroparesis Market Segmentation

SAM Gastroparesis Market - By Type

  • Idiopathic
  • Diabetic
  • Post-surgical
  • Others

SAM Gastroparesis Market - By Drug Class

  • Prokinetic Agents
  • Botulinum Toxin Injections
  • Antiemetic Agent

SAM Gastroparesis Market – By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

SAM Gastroparesis Market - By Country

  • Brazil
  • Argentina
  • Rest of SAM

SAM Gastroparesis Market - Company Profiles

  • Allergan Plc
  • Bausch Health Companies Inc. (Salix Pharmaceuticals, Ltd.)
  • Ipca Laboratories Ltd.
  • Johnson and Johnson Services, Inc.
  • Pfizer Inc.
  • TEVA PHARMACEUTICAL INDUSTRIES LTD 
 

1.           Introduction

1.1         Scope of the Study

1.2         The Insight Partners Research Report Guidance

1.3         Market Segmentation

1.3.1        SAM Gastroparesis Market – By Type

1.3.2        SAM Gastroparesis Market – By Drug Class Type

1.3.3        SAM Gastroparesis Market – By Distribution Channel

1.3.4        SAM Gastroparesis Market – By Country

2.           SAM Gastroparesis Market – Key Takeaways

3.           Research Methodology

3.1         Coverage

3.2         Secondary Research

3.3         Primary Research

4.           SAM Gastroparesis Market – Market Landscape

4.1         Overview

4.2         SAM PEST Analysis

4.3         Expert Opinion

5.           SAM Gastroparesis Market – Key Market Dynamics

5.1         Market Drivers

5.1.1        Diabetes Mellitus Rising at Swift Pace

5.1.2        Geriatric Population Growing

5.2         Market Restraints

5.2.1        Gastroparesis Drugs Showing Various Side Effects

5.3         Market Opportunities

5.3.1        Significant Financial Assistance for Research Work

5.4         Future Trends

5.4.1        Gastric Electrical Stimulation Therapy Research Taken Seriously

5.5         Impact Analysis

6.           Gastroparesis Market – SAM Analysis

6.1         SAM Gastroparesis Market Revenue Forecast and Analysis

7.           SAM Gastroparesis Market Analysis – By Type

7.1         Overview

7.2         SAM Gastroparesis Market Revenue Share, by Type (2019 and 2027)

7.3         Idiopathic

7.3.1        Overview

7.3.2        Idiopathic: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)

7.4         Diabetic

7.4.1        Overview

7.4.2        Diabetic: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)

7.5         Post-Surgical

7.5.1        Overview

7.5.2        Post-Surgical: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)

7.6         Others

7.6.1        Overview

7.6.2        Others: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)

8.           SAM Gastroparesis Market Analysis – By Drug Class Type

8.1         Overview

8.2         SAM Gastroparesis Market Revenue Share, by Drug Class Type (2019 and 2027)

8.3         Prokinetic Agents

8.3.1        Overview

8.3.2        Prokinetic Agents: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)

8.4         Botulinum Toxin Injection

8.4.1        Overview

8.4.2        Botulinum Toxin Injection: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)

8.5         Antiemetic Agents

8.5.1        Overview

8.5.2        Antiemetic Agents: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)

9.           SAM Gastroparesis Market Analysis – By Distribution Channel

9.1         Overview

9.2         SAM Gastroparesis Market Share, by Distribution Channel, 2019 and 2027, (%)

9.3         Retail Pharmacies

9.3.1        Overview

9.3.2        Retail Pharmacies: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)

9.4         Hospital Pharmacies

9.4.1        Overview

9.4.2        Hospital Pharmacies: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)

9.5         Others

9.5.1        Overview

9.5.2        Others: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)

10.        SAM Gastroparesis Market – Country Analysis

10.1      Overview

10.1.1     SAM: Gastroparesis Market, by Country, 2019 & 2027 (%)

10.1.2     Brazil: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)

10.1.2.1       Brazil: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)

10.1.2.2       Brazil Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)

10.1.2.3       Brazil Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)

10.1.2.4       Brazil Gastroparesis Market, by Distribution Channel– Revenue and Forecast to 2027 (USD Million)

10.1.3     Argentina: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)

10.1.3.1       Argentina: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)

10.1.3.2       Argentina Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)

10.1.3.3       Argentina Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)

10.1.3.4       Argentina Gastroparesis Market, by Distribution Channel– Revenue and Forecast to 2027 (USD Million)

10.1.3.5       Rest of SAM: Gastroparesis Market- Revenue and Forecasts to 2027 (USD Million)

10.1.3.6       Rest of SAM: Gastroparesis Market- Revenue and Forecasts to 2027 (USD Million)

10.1.3.7       Rest of SAM Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)

10.1.3.8       Rest of SAM Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)

10.1.3.9       Rest of SAM Gastroparesis Market, by Distribution Channel– Revenue and Forecast to 2027 (USD Million)

11.        Impact of COVID-19 Pandemic on Global Gastroparesis Market

11.1      SAM: Impact Assessment of COVID-19 Pandemic

12.        Gastroparesis Market –Industry Landscape

12.1      Overview

12.2      Growth Strategies in the Gastroparesis Market, 2018-2020

12.3      Inorganic Growth Strategies

12.3.1     Overview

12.4      Organic Growth Strategies

12.4.1     Overview

13.        Company Profiles

13.1      Allergan Plc.

13.1.1     Key Facts

13.1.2     Business Description

13.1.3     Products and Services

13.1.4     Financial Overview

13.1.5     SWOT Analysis

13.1.6     Key Developments

13.2      Bausch Health Companies Inc. (Salix Pharmaceuticals)

13.2.1     Key Facts

13.2.2     Business Description

13.2.3     Products and Services

13.2.4     Financial Overview

13.2.5     SWOT Analysis

13.2.6     Key Developments

13.3      Johnson and Johnson Services, Inc.

13.3.1     Key Facts

13.3.2     Business Description

13.3.3     Products and Services

13.3.4     Financial Overview

13.3.5     SWOT Analysis

13.3.6     Key Developments

13.4      TEVA PHARMACEUTICAL INDUSTRIES LTD

13.4.1     Key Facts

13.4.2     Business Description

13.4.3     Products and Services

13.4.4     Financial Overview

13.4.5     SWOT Analysis

13.4.6     Key Developments

13.5      Pfizer Inc.

13.5.1     Key Facts

13.5.2     Business Description

13.5.3     Products and Services

13.5.4     Financial Overview

13.5.5     SWOT Analysis

13.5.6     Key Developments

13.6      Ipca Laboratories Ltd

13.6.1     Key Facts

13.6.2     Business Description

13.6.3     Products and Services

13.6.4     Financial Overview

13.6.5     SWOT Analysis

13.6.6     Key Developments

14.        Appendix

14.1      About the Insight Partners

14.2      Glossary of Terms

LIST OF TABLES

Table 1.             Brazil Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)

Table 2.             Brazil Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)

Table 3.             Brazil Gastroparesis Market, by Distribution Channel– Revenue and Forecast to 2027 (USD Million)

Table 4.             Argentina Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)

Table 5.             Argentina Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)

Table 6.             Argentina Gastroparesis Market, by Distribution Channel– Revenue and Forecast to 2027 (USD Million)

Table 7.             Rest of SAM Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)

Table 8.             Rest of SAM Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)

Table 9.             Rest of SAM Gastroparesis Market, by Distribution Channel– Revenue and Forecast to 2027 (USD Million)

Table 10.          Recent Inorganic Growth Strategies in the Gastroparesis market

Table 11.          Glossary of Terms, Gastroparesis Market

LIST OF FIGURES

Figure 1.           SAM Gastroparesis Market Segmentation

Figure 2.           SAM Gastroparesis Market Segmentation, By Country

Figure 3.           SAM Gastroparesis Market Overview

Figure 4.           Idiopathic Segment Held Largest Share of SAM Gastroparesis Market

Figure 5.           Brazil to Show Remarkable Growth During Forecast Period

Figure 6.           SAM PEST Analysis

Figure 7.           SAM Gastroparesis Market Impact Analysis of Drivers and Restraints

Figure 8.           SAM Gastroparesis Market – Revenue Forecast And Analysis – 2019- 2027

Figure 9.           SAM Gastroparesis Market Revenue Share, by Type (2019 and 2027)

Figure 10.        SAM Idiopathic: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)

Figure 11.        SAM Diabetic: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)

Figure 12.        SAM Post-Surgical: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)

Figure 13.        SAM Others: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)

Figure 14.        SAM Gastroparesis Market Revenue Share, by Drug Class Type (2019 and 2027)

Figure 15.        SAM Prokinetic Agents: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)

Figure 16.        SAM Botulinum Toxin Injection: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)

Figure 17.        SAM Antiemetic Agents: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)

Figure 18.        SAM Gastroparesis Market Share, by Distribution Channel, 2019 and 2027 (%)

Figure 19.        SAM Retail Pharmacies: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)

Figure 20.        SAM Hospital Pharmacies: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)

Figure 21.        SAM Others: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)

Figure 22.        SAM: Gastroparesis Market, by Key Country – Revenue (2019) (US$ Million)

Figure 23.        SAM: Gastroparesis Market, by Country, 2019 & 2027 (%)

Figure 24.        Brazil: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)

Figure 25.        Argentina: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)

Figure 26.        Rest of SAM: Gastroparesis Market- Revenue And Forecasts To 2027 (USD Million)

Figure 27.        Impact Of COVID-19 Pandemic in SAM Market

Figure 28.        Growth Strategies in the Gastroparesis Market, 2018-2020

  1. Allergan Plc
  2. Bausch Health Companies Inc. (Salix Pharmaceuticals, Ltd.)
  3. Ipca Laboratories Ltd.
  4. Johnson and Johnson Services, Inc.
  5. Pfizer Inc.
  6. TEVA PHARMACEUTICAL INDUSTRIES LTD
  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the SAM gastroparesis market
  • Highlights key business priorities in order to assist companies to realign their business strategies
  • The key findings and recommendations highlight crucial progressive industry trends in the SAM gastroparesis market, thereby allowing players across the value chain to develop effective long-term strategies
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
  • Scrutinize in-depth SAM market trends and outlook coupled with the factors driving the gastroparesis market, as well as those hindering it
  • Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution
Report Code
Full Name
Country Name
Email Id
Phone Number
Job Title
Company
Requirement

Note : Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.


Purchase Options
Single User License
$3000
$1800
Site License
$4000
$2400
Enterprise License
$5000
$3000